No black box warning on record for Ajovy

As of the latest FDA labeling reviewed, Ajovy (FREMANEZUMAB-VFRM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Ajovy medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Most reactions were reported from within hours to one month after administration. If hypersensitivity occurs, consider discontinuing AJOVY and institute appropriate therapy. ( 5.1 ) Hypertension: New-onset or worsening of pre-existing hypertension may occur. ( 5.2 ) Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenome

No black box warning on record for Ajovy

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Most reactions were reported from within hours to one month after administration. If hypersensitivity occurs, consider discontinuing AJOVY and institute appropriate therapy. ( 5.1 ) Hypertension: New-onset or worsening of pre-existing hypertension may occur. ( 5.2 ) Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenome

Ajovy Black Box Warning

No black box warning on record for Ajovy

Other warnings & precautions

Ajovy Black Box Warning

No black box warning on record for Ajovy

Other warnings & precautions